Deal Structure:
As per the agreement, ANI will acquire Alimera for
Along with the cash, Alimera shareholders will receive one non-tradable contingent value right (CVR) of up to
Strategic Rationale
Founded in 2003,
Market Impact
The acquisition is expected to close in the second half of 2024, subject to regulatory approvals and customary closing conditions. Analysts predict that this deal will significantly enhance
Industry experts view this acquisition as a strategic move to capitalize on the growing demand for ophthalmic treatments, driven by an aging population and increasing prevalence of diabetes-related eye conditions. The global diabetic macular edema market alone is projected to reach
Financial Outlook
The acquisition is anticipated to be accretive to
Moreover, the deal is expected to strengthen
Deal Details and Timeline:
ANI expects this acquisition to add about
Alimera's current EV/EBITDA (TTM) ratio is 21.82, above the sector median of 15.48.
The deal, expected to close late in the third quarter of 2024, will help ANI expand its reach to the European and Middle Eastern markets through Alimera's reach.
Deal Metrics:
For more details regarding this M&A transaction, please visit the Deal Metrics page here @ https://www.insidearbitrage.com/2024/06/ani-pharmaceuticals-to-acquire-alimera-sciences-for-381-million/
The Deal Metrics page for each merger or acquisition includes:
- A spread history chart of the merger from announcement through eventual completion or failure. - Every event as the merger progresses through the expiration of the HSR period, various regulatory approvals, shareholder votes, etc. - News and
About InsideArbitrage:
InsideArbitrage is a leading platform for investment insights and education, offering curated reading lists, analysis, and premium tools for investors seeking to enhance their knowledge of special situations investing that includes the strategies of merger arbitrage, legal insider transactions, spinoffs, management transitions, stock buybacks and SPACs.
Inside Arbitrage provides access to six different event-driven strategies to expand your investing toolbox, special situations focused tools, qualitative writeups of ideas through weekly articles, and a comprehensive monthly newsletter.
Disclaimer: This press release includes forward-looking statements within the meaning of applicable securities laws. Forward-looking statements can generally be identified by the use of words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," "will," or similar expressions. These statements are based on the current expectations and beliefs of
This content does not constitute financial advice, investment advice, or any other kind of advice, and should not be relied upon as such. Readers are encouraged to conduct their own research and seek professional guidance before making any investment decisions. The completion of the transaction is subject to various conditions, including shareholder and regulatory approvals, and there can be no assurances that the transaction will be completed as described. Neither the author nor the publishing platform assumes any responsibility or liability for any errors or omissions in the content of this press release.
Media Contact
Company
Contact Person:
Email: sameer@insidearbitrage.com
Phone: +1 (541) 221-2902
Country:
Website: www.insidearbitrage.com
Source: www.abnewswire.com
.
(C) 2024 M2 COMMUNICATIONS, source